China Biopharmaceutical Industry Report, 2007-2008
  • Dec/2007
  • Hard Copy
  • USD $1,900
  • Pages:95
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: FB001
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,100
      

Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are strengthening their presence worldwide. Compared with traditional pharmaceutical industry, biopharmaceutical industry sees a higher market concentration, and this is more helpful for strong enterprises to grow stronger and for building a number of leading enterprises in the segment areas. Currently, traditional chemical pharmaceutical makers also start turning their eyes towards biopharmaceutical field, and keep themselves busy in establishing much more strategic alliance.

China's pharmaceutical industry has been growing at 20% on the average in production value over the past decade, nearly doubled every four years. In Jan-Jul 2007, the accumulated production value of the entire industry reached RMB 342.449 billion, up 23.47% compared to the same period of last year, of which, production value of bio-pharmaceuticals was RMB 30.229 billion, up 24.37% from a year earlier.

Total Industrial Output Value and Growth, Jan-Jul 2007

 
 
Source: State Information Center

China's biopharmaceutical industry could not only produce internationally important biologic drugs, but develop independently new biological drugs. Furthermore, China has achieved great breakthrough in gene engineering, biopharmaceuticals and clone technology. Despite of the rapid growth, there are still serious problems in China's biopharmaceutical industry:

China is weak in the investment, R&D capability and technology innovation;
There are serious repeated construction problems in drug development and production;
Overall, enterprises are small-sized, and with low modernization level and outmoded equipments;
Marketing strategies are unreasonable, mainly in brand development;
Management is outdated and talents capable of both technology and operation fall short;
 There are no enough exchange and cooperation among enterprises.

Biopharmaceutical industry includes four segment markets: gene engineering, bacterin, blood products and diagnostic reagent. After more than a decade of development, these four segment markets find many aggressive private or state-owned biopharmaceutical enterprises through which China is to fulfill its supports to the whole industry. As far as capital market is concerned, as concept investment bubble fades away, Chinese pharmaceutical enterprises are expected to be gradually accepted by the market with its high growth potentials.

Polices have a great influence on China's biopharmaceutical industry, so how many efforts China will make to support the industry plays a significant role in its development. In fact, China always keeps a close eye on biopharmaceutical industry and has frequently issued related policies in recent two years, which is very positive for stimulating the development of biopharmaceutical industry and for regulating industry rules, and also brings energy and opportunities into the biopharmaceutical industry.

Related Laws and Regulations Issued in 2007

 
 

Based on the study on China pharmaceutical industry's status quo, competitive pattern, investment and developing trend, this report puts its emphasis on output and sales situation of main drugs, impact China's pharmaceutical industry will face as well as strategies enterprises should make.

1 Operation Status of China Pharmaceutical Industry in 2007
1.1 Overview
1.2 Problems in China pharmaceutical market
1.2.1 Competition in production is rampant
1.2.2 Capability in innovation is poor
1.2.3 Drug quality appears thread-and-thrum
1.2.4 Financing channel is undiversified and investment is in short
1.2.5 Drug circulation market is unorderly
1.3 Policies adjustment in China's pharmaceutical industry in 2007

2 Overview of Biopharmaceutical Industry
2.1 Brief introduction to biopharmaceutical industry
2.1.1 Definition
2.1.2 Development history
2.2 Main products and characteristics of biopharmaceutical industry
2.2.1 Main products
2.2.2 Characteristics
2.3 Development status of global pharmaceutical industry
2.3.1 USA
2.3.2 Europe
2.3.3 Japan
2.3.4 India

3 Environments in China Biopharmaceutical Industry
3.1 Macro environments
3.1.1 General situation of macroeconomic in China, 2007
3.1.2 Economic operations of China pharmaceutical industry
3.1.3 Influences caused by variational macro environments in China medical treatment field
3.2 Policy environments
3.2.1 Drug registration
3.2.2 Drug production
3.3.3 Drug circulation
3.3.4 Drug application
3.2.5 Supervision on sub-industries

4 Status Quo of China Biopharmaceutical Industry
4.1 Operations
4.2 Production technology
4.3 Major problems
4.3.1 Enterprises operate mostly at a small size
4.3.2 Repeated construction problems are serious
4.3.3 R&D capability is weak
4.3.4 Industry concentration is at a low level
4.3.5 Basic R&D results are unable to be converted efficiently

5 Industrial Systems in China Biopharmaceutical Industry
5.1 Biopharmaceutical industry systems
5.2 Problems exist in China biopharmaceutical industry systems
5.3 Value chain analysis in biopharmaceutical industry

6 Main biopharmaceutical products
6.1 Blood products
6.1.1 Operations status
6.1.2 Main blood products
6.1.3 Competitiveness
6.2 Bacterin
6.2.1 Overview of Bacterin market
6.2.2 Polices on immunity plan promote bacterin market to grow fast
6.2.3 Market competitiveness
6.2.4 Segment markets

7 Listed Companies
7.1 Hualan Biological Engineering Inc.
7.1.1 Company Profile
7.1.2 Operations in 2007
7.1.3 Opportunities and risks
7.2 Shanghai Kehua Bio-engineering Co., Ltd
7.2.1 Company profile
7.2.2 Operations in 2007
7.2.3 Risks
7.3 Beijing Tiantan Biological Products Co., Ltd
7.3.1 Company profile
7.3.2 Operations in 2007
7.3.3 Opportunities and risks
7.4 Da An Gene Co., Ltd of Sun Yat-Sen University
7.4.1 Company profile
7.4.2 Operations in 2007
7.4.3 Opportunities and risks

8 Foreign Companies in China
8.1 Bayer
8.1.1 Operations in China
8.1.2 Investments in China
8.2 AstraZeneca
8.3 Pfizer
8.3.1 Operations in China
8.3.2 Investments in China
8.4 Sanofipasteur
8.5 Novartis
8.6 GlaxoSmithKline (GSK)
8.7 Lilly
8.8 Co-operative Group
Revenue and Profit Growth of Pharmaceutical Industry by Segment, Jan-Aug 2007
Growth of Sales Revenue and Gross Profit of Pharmaceutical Industry
Per Capita GDP and Medical Care Depending/GDP Worldwide
Forecast on Trend of Proportion of Total Health Expenditure to GDP in China
Total Sum Spent by Sample Hospitals on Albumin Market
Ranking of Drugs Used by Hospitals by Purchase Sum, 2006
Price Trend of Albumin
Product Structure of Blood Products Market in China, 2006
Product Structure of Blood Products Market in the World, 2006
PCC Market Share by Manufacturer, 2006
IVIG Market Share by Manufacturer, 2006
HRIG Market Share by Manufacturer, 2006
List of Blood Products Manufacturers in China
Total Amount of Plasma in China
Product Structure of Key Blood Products Manufacturers
Share of Sample Hospitals in Albumin Market, 2006
Main Brands of Imported Human Serum Albumin Injections in China
Newly-increased Bacterins after Starting the Expanded Program on Immunization
Number of Manufacturers by Main Bacterin
Key Projects in Process
Main Business Revenue and Gross Profit Margin by Company
Profitability Indices by Company
Indices of Operating Ability and Debt-Paying Ability by Company
Product Structure Change by Company
Shareholding Structure of Da An Gene Co., Ltd of Sun Yat-Sen University
Financial Indices of Listed Diagnostic Reagents Companies, 2007H1
Forecast on Da An Gene's Diagnostic Reagents Development
Key PCR Reagents Manufacturers in China
Comparison of In-Vitro Diagnostic Methods
Catalog of PCR Reagents Reported by Da An Gene to State Food and Drug Administration, 2006-2007
Penetration Status of Medical Insurance System
Population and Structure in China
Engel's Coefficient Change in China
Per Capita Health Expenditure in China, 2000-2004
Major Laws and Regulations Issued in 2007
Market Capacity of Segmented Blood Products
Supervision Policies on Blood Products

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统